title: Effect of fluvastatin on long-term outcome after coronary revascularization with stent implantation.
abstract: We assessed the impact of long-term fluvastatin treatment on adverse atherosclerotic cardiac events (cardiac death, myocardial infarction, and revascularization excluding repeat interventions due to restenosis in the first 6 months) in 847 patients (fluvastatin [n = 417] or placebo [n = 430]) with average cholesterol levels treated with stents in the Lescol Intervention Prevention Study (LIPS). During the 4-year follow-up period, fluvastatin significantly decreased total cholesterol and low-density lipoprotein cholesterol levels and decreased the risk of first adverse atherosclerotic cardiac events by 30% compared with placebo (95% confidence interval -49 to -3.4, p = 0.03).
authors.affiliation: Erasmus MC, Thoraxcenter, Rotterdam, The Netherlands.
authors.forename: Francesco
authors.initials: F
authors.lastname: Saia
authors.forename: Pim
authors.initials: P
authors.lastname: de Feyter
authors.forename: Patrick W
authors.initials: PW
authors.lastname: Serruys
authors.forename: Pedro A
authors.initials: PA
authors.lastname: Lemos
authors.forename: Chourmouzios A
authors.initials: CA
authors.lastname: Arampatzis
authors.forename: Guy R
authors.initials: GR
authors.lastname: Hendrickx
authors.forename: Nicholas
authors.initials: N
authors.lastname: Delarche
authors.forename: Dick
authors.initials: D
authors.lastname: Goedhart
authors.forename: Emmanuel
authors.initials: E
authors.lastname: Lesaffre
authors.forename: Angelo
authors.initials: A
authors.lastname: Branzi
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000924:Anticholesteremic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D001938:Brazil; D002170:Canada; D002784:Cholesterol / Q000097:blood; D008076:Cholesterol, HDL / Q000097:blood; D008078:Cholesterol, LDL / Q000097:blood; D003324:Coronary Artery Disease / Q000097:blood / Q000000981:diagnostic imaging / Q000473:pathology / Q000628:therapy*; D004334:Drug Administration Schedule; D005060:Europe; D005229:Fatty Acids, Monounsaturated / Q000008:administration & dosage / Q000627:therapeutic use*; D005260:Female; D000077340:Fluvastatin; D006801:Humans; D007211:Indoles / Q000008:administration & dosage / Q000627:therapeutic use*; D008137:Longitudinal Studies; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000401:mortality / Q000517:prevention & control*; D009204:Myocardial Revascularization; D011859:Radiography; D012720:Severity of Illness Index; D015607:Stents; D016896:Treatment Outcome; D014280:Triglycerides / Q000097:blood
chemical_list: D000924:Anticholesteremic Agents; D008076:Cholesterol, HDL; D008078:Cholesterol, LDL; D005229:Fatty Acids, Monounsaturated; D007211:Indoles; D014280:Triglycerides; D000077340:Fluvastatin; D002784:Cholesterol